Becton, Dickinson and Company (NYSE:BDX) Releases Quarterly Earnings Results, Beats Expectations By $0.43 EPS

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings results on Wednesday. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43, Zacks reports. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company updated its FY 2025 guidance to 14.300-14.600 EPS.

Becton, Dickinson and Company Price Performance

NYSE BDX traded up $2.65 on Wednesday, hitting $245.07. 2,061,265 shares of the company were exchanged, compared to its average volume of 2,046,401. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The firm has a 50 day moving average of $231.33 and a two-hundred day moving average of $234.02. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The company has a market cap of $71.07 billion, a P/E ratio of 41.26, a P/E/G ratio of 1.80 and a beta of 0.40.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.70%. Becton, Dickinson and Company’s payout ratio is presently 70.03%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the transaction, the executive vice president now owns 16,201 shares of the company’s stock, valued at $3,807,235. The trade was a 4.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares in the company, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,844 shares of company stock worth $2,210,716. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research firms recently commented on BDX. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler increased their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.